The vast majority of patients affected by FLT3-ITDmut AML, in remission after first-line or salvage chemotherapy, relapse if they do not receive HSCT, which therefore remains the cornerstone of treatment of the disease [30]. The gene discussed is FLT3; the disease is acute myeloid leukemia.